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Introduction
A recent scientific statement from the American Heart Association (AHA) and American 
Stroke Association (ASA) highlighted the significance of vascular contributions to cognitive 
impairment and dementia (1), coined “VCID” here and referred to as vascular dementia 
and/or vascular cognitive impairment and/or vascular contributions to dementia 
alternatively. The concept for VCID emerged as a leading priority at the National Institutes 
of Health (NIH) National Institute of Neurological Disorders and Stroke (NINDS) hosted 
Stroke Research Priorities Meeting (2) and also at the 2013 the Alzheimer’s Disease-Related 
Dementia (ADRD) Summit. The ADRD Summit set research priorities for small vessel 
VCID research over the next 5–10 years: develop the next generation experimental models, 
encourage basic science investigation on the impact of AD risk factors on cerebrovascular 
function and vice versa (3, 4). The Alzheimer’s Association, with scientific input from the 
NINDS and the National Heart, Lung and Blood Institute (NHLBI), convened a panel of 
cross-disciplinary experts in Chicago, IL, on December 17th, 2013 to determine the state of 
the science and to identify the needed step, including unanswered research questions, which 
will translate into improved clinical outcomes related to small vessel VCID. This manuscript 
summarizes the proceedings of this discussion.
State of the science
Decades of data, including landmark work of the Honolulu Asia Aging Study (HAAS), the 
Rotterdam Study (20), and the Religious Orders Study and Memory and Aging Project 
(ROS/MAP) (12, 13) have provided significant insight into potential links of vascular 
factors to dementia, such as AD. An important risk factor for dementia was the presence of 
lacunar and larger cerebral infarcts in the brain that are pathologic markers of clinical or 
subclinical stroke (5–7, 20). Others have subsequently shown that ischemic brain injury, 
commonly detected in pathology as macro- and micro- infarcts and vessel disease, e.g. 
atherosclerosis, arteriosclerosis, and cerebral amyloid angiopathy [CAA], are highly 
prevalent in older persons and are independent risk factors for cognitive dysfunction and 
dementia (17–23).
Mixed vascular and AD etiology dementia is one the common dementia in older persons, 
and becomes even more common as age increases as both vascular and AD pathologies 
accumulate over time (10)(11). For example, in the longitudinal ROS/MAP, over half of the 
individuals with AD had a combination of both AD and vascular pathologies (12, 13). 
Importantly, the deleterious effect of vascular pathologies combined with AD pathology 
leads to increased likelihood of dementia; this is true for both large infarcts (commonly 
manifested as stroke) and micro infarcts in individuals with similar levels of AD 
neuropathology (14, 15). Vascular lesions detected by imaging, in particular small vessel 
and microvascular white matter damage, typically detected in current clinical settings as 
type 2 hyperintensities on MRI, and also as leukoaraiosis detected by CT, are also highly 
prevalent in the elderly, and worsening is associated with cognitive decline (16). Addition of 
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either arteriosclerosis or atherosclerosis results in further increased likelihood of micro 
infarcts, and an even higher probability of dementia.
The plot thickens: Molecular and vascular mechanisms
Molecular mechanisms associated with the vasculature and with accumulating AD 
pathologies have been linked in several ways and may be linked to the increased neuronal 
death observed in the mixed etiology. Decreased blood flow prior to beta-amyloid (Aβ) 
deposition has been observed in the brain of both mouse models of AD and in individuals 
with AD, and has been proposed to contribute directly to the cognitive symptoms and, some 
studies suggest the changes in the vasculature impair clearance of Aβ, and thereby accelerate 
the progression of AD (60, 61)(62, 63). Adding to this picture is considerable evidence that 
type 2 diabetes mellitus (T2DM) and insulin resistance are linked to an increased risk of 
vascular disease, AD pathology, and dementia (24)(25)(26).
Molecular mechanisms that may be related have been further supported by recent genetic 
studies. The International Genomics of Alzheimer’s Project (I-GAP), funded in part by the 
Alzheimer’s Association, published a meta-analysis of data from nearly 75,000 individuals 
and identified 21 genetic risk loci for late-onset AD (LOAD)(31). Individuals with small 
vessel cerebrovascular disease were not excluded because it is integral with a large 
proportion of AD, as discussed above. However, pathologic analysis of a subset of I-GAP 
individuals enabled comparison of the odds ratio (OR) for AD dementia for each of the 
genetic loci based on clinical diagnosis alone, clinical plus standard pathological definition 
(plaques and tangles), or more criteria that take into account vascular pathology. 
Interestingly, for individuals with vascular lesions the OR of specific genetic loci were 
different, increased or decreased, versus OR calculated using “pure” AD-pathology subjects, 
suggesting that some loci may function and respond differently with respect to vascular vs. 
AD-specific (i.e. plaques and tangles) pathology. Further investigation is needed to 
understand the linkage of underlying mechanisms with these pathological changes.
The innate immune system has also been implicated as a potential connection point between 
AD and vascular disease. Innate immunity is activated both in cerebrovascular disease (34) 
and in AD, in which postmortem studies show chronic inflammation characterized by an 
influx of activated microglia and infiltrating monocytes around plaques and tangles (32). 
Lue and colleagues reported that plaques and tangles appear only to cause 
neurodegeneration when inflammation is also present (33). While it is unclear whether 
recruitment of the innate immune system is a response to damage or pathogenic in nature, 
large GWAS studies suggest innate immune cells, including resident microglia and 
infiltrating monocytes and may drive AD pathogenesis through vascular related mechanisms 
that we are just beginning to understand (35) (36). A potential linkage between the immune 
infiltration and VCID may be the disruption of the blood brain barrier (BBB), demonstrated 
in post-mortem brain tissue studies of individuals with AD-related cognitive impairment, 
although the mechanism and timing has been unclear (41–45)(46).
The brain is the most lipid rich organ in the body and has a specialized system to carry fats; 
several lines of evidence suggest that lipid and lipoprotein metabolism may provide key 
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insight into VCID and AD. Lipid metabolism has long been implicated in AD; APOE is both 
a known genetic risk factor for late onset AD and is a primary lipid carrier in the brain (37). 
ApoE4, the product of the detrimental APOE allele, has multiple neuropathological effects 
in the central nervous system, including a loss of cerebrovascular integrity and breakdown 
of the BBB (38). Mechanistically, the proinflammatory cyclophylin A (CypA)-matrix 
metalloproteinase-9 (MMP-9) pathway is activated in pericytes in transgenic humanized 
APOE4 knock-in mice, leading to degradation of endothelial tight junctions as well as 
basement membrane proteins, and thus disruption of the BBB (39). Consistent with findings 
in transgenic APOE4 mice, a recent study in cognitively normal humans found age-
dependent BBB breakdown in APOE4 carriers vs. non-APOE4 carriers, as indicated by an 
increased CSF/plasma albumin ratio and increased CypA and MMP-9 levels in the CSF 
(40). Irrespective of mechanism, BBB disruption exposes the brain parenchyma to 
potentially neurotoxic blood proteins, e.g. thrombin, fibrin, plasmin and hemoglobin, as well 
as the iron from lysed erythrocytes (i.e., siderosis)(47).
The cholesterol transporter ABCA1 delivers lipids to ApoE as well as ApoA-I, the primary 
protein component of HDL (“good cholesterol”). ApoE and ApoA-I in turn transport 
cholesterol from organs and arterial walls to the liver for excretion (49). In ABCA1 deficient 
mice, ApoE particles in the blood cannot become lipidated, ultimately resulting in increased 
amyloid burden in the dentate gyrus; conversely, in mice that overexpress ABCA1, this 
amyloid burden is nearly eliminated. Thus, drug discovery programs are looking for ways to 
increase ABCA1 expression, for example by using Liver X Receptor or LXR agonists (50). 
Like ApoE, ApoAI may also play an important role in vascular contributions to brain health, 
as indicated by studies of APOA-I/APOA-I knockout mice crossed with the Amyloid 
Precursor Protein (APP)/PS1ΔE9 transgenic AD mouse model (48) (51). As ApoA-I and 
high density lipoprotein (HDL) protect endothelial function in large peripheral vessels (52), 
HDL appears to also promote endothelial repair in healthy subjects (54, 55); to affect 
activity of the innate immune system; to have anti-inflammatory and antioxidant functions 
(52, 54) (53). Taken together, understanding the roles of ApoA-I and HDL in neurovascular 
physiology is an important priority.
Cerebral pial collateral circulation has a special role in limiting damage due to 
cerebrovascular occlusion. The adverse hemodynamic environment present in the pia limits 
collateral circulation under normal condition, but when brain circulation is compromised, 
e.g. in an ischemic event, these pial collaterals can facilitate compensatory blood perfusion 
in brain regions that would otherwise be (even more) compromised. Genetic and 
environmental factors can combine to limit the anatomical extent and capacity of pial 
collaterals for compensatory circulation, and thus significantly increase severity of brain 
injury in occlusive vascular disease (56, 57). For example, aging causes rarefaction of 
collateral vessels associated with dysfunctional nitric oxide synthase signaling and increased 
collateral tortuosity and resistance, increasing severity of ischemic injury (58), and genetic 
variation has been shown to influence and limit the extent of compensatory collateral 
circulation (59).
An emerging area of interest in cerebrovascular circulation in health and disease that may 
help identify novel drug targets is clearance of parenchymal waste, including Aβ, into the 
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CSF via perivascular circulation [also referred to as the glymphatic system (65, 66)]. Xie 
and colleagues demonstrated glymphatic Aβ clearance occurs during sleep (67), correlating 
with findings that both AD and VCID are linked to sleep disturbances (68). In addition to 
this potential role for the glymphatic system, BBB transport of Aβ from the parenchyma 
directly into vascular circulation is severely compromised in transgenic AD mouse models, 
and is a significant area for potential therapeutic development (69, 70). In the vasculature 
itself, another emerging topic with novel potential for intervention is stalled blood flow in 
brain capillaries due to leukocyte adherence to the endothelial lumen wall (64). When 
leukocytes adhere to the endothelium due to inflammation, only a small number of affected 
capillaries in the brain can result in significant decreases in downstream blood flow (64).
Animal models as a research tool
The VCID field has a need to model vascular factors, both genetic and non-genetic, to create 
novel models of mixed dementia representing the human disorder, in particular, for the 
purposes here, small vessel VCID. Several types of vascular models are currently used to 
study how vascular disease ay contributes to dementia: middle cerebral artery occlusion 
(MCAO) mouse model of stroke (71)(72); the bilateral common carotid stenosis (BCAS) 
model that creates chronic cerebral hypoperfusion (73); several mutant APP transgenic mice 
that develop CAA and CAA-related cerebrovascular deficits in addition to classic 
parenchymal Aβ pathology (74); and, finally, the Dutch APP mutation mouse model of 
CAA that develops extensive vascular Aβ deposits at an advanced age, but develop very few 
parenchymal Aβ plaques (75). There is also a more aggressive mouse model of CAA that 
includes Aβ accumulation in the vessel wall (76). Rosenberg and colleagues developed 
Another potential model are rats fed the Japanese Permissive Diet (JPD) of low protein and 
high salt, as they develop spontaneous hypertensive/stroke (SHR/SP) with unilateral carotid 
occlusion and white matter damage that evolves over weeks to months (77).
Yet another model of cardiovascular disease, wild type mice fed a diet deficient in B6, B12 
and folic acid to drive a condition of hyperhomocysteinemia, which is implicated as a 
potential risk factor for cardiovascular disease, stroke, T2DM, vascular dementia, and AD 
(78). Feeding this diet to a transgenic mouse overexpressing APP resulted in an induction of 
a proinflammatory state and a change in the distribution of amyloid. Further, these mice 
have cognitive impairments and an increased number of microhemorrhages. Hypertensive 
animal models, such as those that display white matter disease, may also be useful, since a 
major risk factor for cerebrovascular disease is hypertension. In this regard, one example of 
a mouse model already used for systemic vascular and cardiac research, that may be useful 
for better understanding VCID, overexpresses renin under an albumin promoter develops an 
allele-dose-dependent hypertension, heart failure and loss of collaterals in the hetero- and 
homozygous strains (79). Despite the utilization of these models, there is lack of clear 
animal model(s) to tease out the role of VCID (such as associated risk factors) in dementia 
onset and progression. As discussed in the below section, the need for new model systems 
with metabolic similarity to humans, such as animal models with white matter vascular 
injury, animal models of hypertension or the potential utility of stem cell/induced pluripotent 
models are in need of further exploration.
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Biomarkers that precede and predict onset and that demonstrate the level of burden and track 
progression of small vessel disease-related brain injuries are the gold standard for the 
scientific community, and such a biomarker would greatly enhance the development of 
interventions for VCID with the greatest impact on AD and the associated high disease 
burden of related mixed dementias with a vascular component. Today, subsets of such 
biomarkers are in early development in clinical research with the ultimate goal of 
transferring to a clinical setting, and there is still much unknown about the longitudinal 
changes associated with VCID that may inform biomarker discovery. Tools such as 
diffusion-weighted magnetic resonance imaging (DWI-MRI) sequences to characterize 
acute/sub-acute microinfarcts (82) and functional MRI (fMRI) to assess impaired vascular 
reactivity associated with CAA (83) are being explored. Another area of exploration, a 
CAA-specific amyloid PET imaging tracer may be useful for diagnosing CAA before 
symptoms become apparent, quantifying CAA burden at the time of symptom presentation, 
monitoring CAA progression over time, and/or assessing response to a CAA-directed 
treatment. During investigation of CAA in mouse models, Zipfel and colleagues identified a 
fluorescent phenoxazine analog called resorufin that preferentially binds to CAA rather than 
parenchymal Aβ (80), and are now working to develop second-generation analogs to 
overcome challenges associated with affinity and solubility. Such tools may provide insight 
into VCID related changes and possible information on the longitudinal progression of these 
changes. Possible other areas of exploration for potential biomarkers may include measures 
related to microinfarcts, microbleeds, siderosis, white matter lesions, microinfarcts, altered 
microstructure, BBB breakdown and pericyte degeneration (shown to play a critical role in 
animal models of AD) (81), endothelial activation, as well as various aspects of immune 
dysfunction and inflammation, blood flow reductions, and vascular compliance. A greater 
understanding of the biological underpinnings discussed above will significantly inform the 
development of novel and informative biomarkers related to VCID.
Summary and next steps
One of the key concepts to emerge from this meeting is the recognition that cerebrovascular 
disease and especially small vessel disease is common in aging, and does not typically occur 
in isolation, but rather is associated with AD. Further there is a broad spectrum of comorbid 
conditions that commonly co-exist with AD and related dementia, including hypertension, 
diabetes, hypercholesterolemia, obesity, low physical activity, depression, and smoking. In 
discussion about how to move the field forward, meeting participants identified two focus 
areas: 1) the need to identify and understand the molecular and cellular mechanisms and 
targets that underlie the contribution of vascular disease to AD and dementia; and 2) the 
need to facilitate development and validation of non-invasive biomarkers of key vascular 
processes related to cognitive and neurologic impairment. For both of these goals, it is clear 
that new research tools are needed, including innovative technical approaches to imaging 
and fluid-based clinical research, and biological tools including humanized animal models, 
including animal models with metabolic similarity to humans, animal models with white 
matter vascular injury, animal models of hypertension; and the potential utility of stem cell/
induced pluripotent models. Tools are needed to answer gaps identified during this meeting:
Snyder et al. Page 6













• Lipid metabolism and its role in amyloid deposition and cognitive/behavioral 
change
• Various roles of different cell types of the innate and adaptive immune systems
• Vascular injury and the response to injury
• Mechanisms for brain blood flow decrease in AD and other dementias
• The role of small vessel disease and blood-brain barrier breakdown
• Effects of reduced blood flow and changes in blood pressure
• Role of and interactions with other risk factors such as diabetes, including study of 
the pre-diabetic brain without the confounding effects of treatment
• Genetic cross-talk between the vasculature and the brain
• Studies of mixed etiology AD dementia
Novel biomarkers are also needed both for investigation of basic science research questions 
and to be developed as potential clinical disease markers. These markers need to be 
validated at an early stage in humans to ensure applicability for human studies:
• Better markers of blood flow, particularly for cerebral small vessels and collateral 
circulation
• A CAA-specific or other imaging compound that recognizes beta-amyloid or other 
markers, specifically and selectively in the cerebrovasculature
• Markers that enable more precise assessment of where pathology occurs in the 
brain parenchyma and blood vessels and the quantitative distribution of pathology
• Biomarkers that detect breakdown or dysfunction of blood-brain barrier 
permeability
• Biomarkers that reflect damage to brain structure and connectivity caused by 
microinfarcts, which are largely undetectable to current neuroimaging
• Vascular biomarkers of AD/dementia risk in prediabetic and insulin-resistant adults
• Improved imaging markers of cerebral vascular dysfunction
• Markers of peripheral circulatory system components that contribute to 
neuroinflammation.
• Improved outcome measures and clinical diagnostic criteria that accurately reflect 
the range of vascular events that impact cognition.
The mobilization of such studies will require significant investments at the federal and 
international levels, with targeted requests for proposals (RFAs) and funding calls. To help 
initiate global commitment of both the funding and the scientific communities, the 
Alzheimer’s Association launched a targeted grant program to fund pilot investigations for 
further discovery, and ultimately, motivate increased new investment by the international 
scientific funding communities into the VCID area of study.
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Future investments for these areas of scientific discovery will be essential to galvanize the 
scientific community and provide forums of communication between the dementia and 
vascular fields. As a next step, focused research sessions and presentations are at various 
stages of planning for annual AD, dementia and cardiovascular focused conferences, 
including the Alzheimer’s Association International Conference (AAIC) and two American 
Heart Association (AHA) conferences, including Atertiosclerosis, Thrombosis, and Vascular 
Biology (ATVB) 2014 and the AHA Scientific Sessions 2014. There is a clear need to both 
convene cross-disciplinary dialogues of the vascular and dementia communities and provide 
opportunities of global investment toward the ultimate goal of successful vascular 
intervention to decrease the burden of AD and other dementias
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